While such options as EPO and supportive treatments are chosen in low-risk MDS patients, other options such as treatments with AZA, decitabine, and venetoclax, intensive induction treatments, and allogeneic stem cell transplantation may be preferred for high-risk MDS patients. Here, EPO is linked to myelodysplastic syndrome.